Alamar Biosciences (ALMR) Net Income — Quarterly & Annual

Screener

Net Income at other companies

Exxon MobilXOM

$4.18B-45.8%

VeradermicsMANE

-$27.23M-120%

GPA

General Purpose Acquisition Corp.GPAC

-$5.23M-37.4%

GPA

General Purpose Acquisition Corp.GPAC

-$5.23M-37.4%

Polaryx Therapeutics, Inc.PLYX

-$2.54M+49.6%

Polaryx Therapeutics, Inc.PLYX

-$2.54M+49.6%

Other financials

Income statement

Revenue$26.0M+98.9%

Gross profit$14.5M+126%

Operating income-$12.3M-44.4%

Net income-$21.3M-178%

EPS (diluted)-$1.74-156%

Balance sheet

Cash & equivalents$64.6M—

Total debt$30.6M—

Total equity-$178.1M—

Total assets$186.5M—

Cash flow

Operating cash flow-$20.3M-55.7%

CapEx$600.0K+8.3%

Free cash flow-$20.9M-53.8%

Valuation

Market cap$1.96B+37.6%

Enterprise value$1.93B—

Returns & leverage

Debt / equity-0.2×—

Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026. Open the filing →

Filed: May 8, 2026, 8:30 AM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001193125-26-213424

FAQ

What is Alamar Biosciences's net income?: Alamar Biosciences (ALMR) reported net income of -$21.33M in Q1 2026.
What does net income mean?: Net income as the starting point for the indirect method operating cash flow reconciliation.

Ask your AI about Alamar Biosciences's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk